Business, energy, technology, markets and global industry news from Business News Today

Oxford University Press

Pharma & Biotech

Can low doses of Ozempic, Wegovy, Mounjaro and Zepbound still cause weight loss?

A new real-world study of sustained low-dose semaglutide and tirzepatide found measurable weight loss without escalation to standard maintenance doses, but researchers stress that prescription records do not prove intentional GLP-1 microdosing and the observational findings cannot establish cause and effect.

Read More